PARP1 and non-small cell lung carcinoma: Some non-small cell lung cancer (NSCLC) patients are acquired resistance to gefitinib, a drug for NSCLC therapy, Sun et al. found that FGL1 was upregulated in gefitinib-resistant cancer cells, and mediated the resistance to gefitinib in NSCLC cells by regulating the PARP1/ Caspase 3 pathway 57.